文献速递泌尿生殖腹部CTMR

多参数MRI在膀胱癌患者中相较增强CT的诊断增益:单中心一年经验

Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience.
PubMed 文献 · Eur J Radiol · 2021-11-20

回顾性纳入33例原发性未治疗膀胱癌患者,术前先后行双期增强CT与3.0T多参数MRI,两名放射科医师以VI-RADS评分系统分期并与术后病理对照。结果显示CT与mpMRI在判断肌层浸润方面各有优劣,敏感度与特异度因医师而异, borderline病例需结合横断面影像与组织病理学分期共同决策。

要点

  • VI-RADS评分可用于膀胱癌肌层浸润的术前评估,但T1-T2a-b交界期病例存在分期误差。
  • mpMRI对肌层浸润判断的敏感度/特异度分别为医师1 74%/61%、医师2 83%/70%。
  • CECT对肌层浸润判断的敏感度/特异度分别为医师1 80%/80%、医师2 70%/90%。

核心结论

  • CECT与mpMRI在膀胱癌肌层浸润的临床评估中各有优缺点;交界性病例仅靠横断面影像与组织病理学分期相结合可能有助于做出最佳治疗决策。

研究设计与样本

  • 单中心回顾性研究,纳入2019年7月至2020年8月间33例原发性未治疗膀胱癌患者,均行双期CECT后行术前3.0T多参数MRI,以术后病理为参考标准。

关键影像表现/征象

  • 最终组织学显示非肌层浸润性膀胱癌10例(30%),肌层浸润性膀胱癌23例(70%)。
  • CECT与mpMRI对Ta-Tis及T3a-T4b期肿瘤的肌层浸润与否均能正确分类。
  • 对T1-T2a-b期(肌层浸润组织病理学交界区)肿瘤,mpMRI图像数据集在43%的病例中高估肌层浸润(VI-RADS 3-4)。
  • 对T1-T2a-b期肿瘤,分析CECT数据时低估肌层浸润的病例高达55.5%。

诊断标准与关键数值

  • 采用五点VI-RADS评分系统对膀胱癌进行分期。
  • CECT判断肌层浸润的敏感度/特异度:医师1为80%/80%,医师2为70%/90%。
  • mpMRI判断肌层浸润的敏感度/特异度:医师1为74%/61%,医师2为83%/70%。
  • 使用卡方检验比较两种影像模态判断肌层浸润的敏感度、特异度和准确率。

临床应用与阅片要点

  • 阅片时需注意T1-T2a-b交界期肿瘤在mpMRI上可能出现肌层浸润高估(VI-RADS 3-4),在CECT上可能出现低估。
  • 报告肌层浸润判断时应结合VI-RADS评分与CECT表现,并注意不同医师间诊断效能存在差异。
  • 对交界性病例,作者认为仅靠横断面影像与组织病理学分期相结合可能有助于做出最佳治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the clinical applicability of local tumor staging in urinary bladder cancer (BC) with preoperative multiparametric MRI (mpMRI) using the five-point Vesical Imaging-Reporting and Data System (VI-RADS) scoring system and to compare it to dual-phase contrast-enhanced computed tomography (CECT).

METHODS: 33 patients with primary untreated bladder cancer underwent CECT followed by preoperative multiparametric 3.0 T MRI between July 2019 and August 2020 and were enrolled in this retrospective study. Two radiologists initially performed staging on the CECT image data sets and - blinded to CT results - on subsequent mpMRI. BCs were staged according to the VI-RADS scoring system. Postoperative pathology was correlated to the VI-RADS score and the CECT results. The performance of VI-RADS in determining detrusor muscle invasion was analyzed using a receiver operating characteristic curve. Based on the histopathology, sensitivity, specificity and accuracy for muscle invasiveness between both image modalities were compared using the Chi square test.

RESULTS: A total of 33 patients (29 male, median age 70 years, IQR: 59-81 years) were included. 10 tumors were categorized as non-muscle invasive (30%) and 23 as muscle invasive BC (70%) in final histology. Tumor stages were correctly assigned as being either muscle invasive or non-muscle invasive on both CECT and mpMRI with regard to both early and late stages of BC (Ta-Tis and T3a-T4b). T-stages bordering the histopathologic limits of muscle invasiveness (T1-T2a-b) resulted in overestimation of muscle invasion in 43% of cases (VI-RADS 3-4) for the mpMRI image data sets and in an underestimation of muscle invasion in up to 55.5% of cases analysing the CECT data. Sensitivity and specificity for the determination of muscle invasion in CECT and mpMRI were 80%/80% and 74%/61% for Radiologist#1 and 70%/90% and 83%/70% for Radiologist#2, respectively.

CONCLUSIONS: There are advantages and disadvantages of both CECT and mpMRI when used in the clinical assessment of BC muscular tumor invasion. In borderline cases, only the combination of cross-sectional imaging and histopathological staging may help in making the optimal treatment decisions.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hagen, Norz, Thaiss, et al. Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. Eur J Radiol. 2021. PMID: 34839167. doi:10.1016/j.ejrad.2021.110059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。